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Abstract
Background: Pneumolysin (PLN) is an intracellular toxin of Streptococcus pneumoniae that has been implicated as a major
virulence factor in infections caused by this pathogen. Conserved bacterial motifs are recognized by the immune system by
pattern recognition receptors among which the family of Toll-like receptors (TLRs) prominently features. The primary
objective of the present study was to determine the role of TLR2 and TLR4 in lung inflammation induced by intrapulmonary
delivery of PLN.
Methodology/Results: First, we confirmed that purified PLN activates cells via TLR4 (not via TLR2) in vitro, using human
embryonic kidney cells transfected with either TLR2 or TLR4. Intranasal administration of PLN induced an inflammatory
response in the pulmonary compartment of mice in vivo, as reflected by influx of neutrophils, release of proinflammatory
cytokines and chemokines, and a rise in total protein concentrations in bronchoalveolar lavage fluid. These PLN-induced
responses were dependent in part, not only on TLR4, but also on TLR2, as indicated by studies using TLR deficient mice.
Conclusion: These data suggest that although purified PLN is recognized by TLR4 in vitro, PLN elicits lung inflammation in
vivo by mechanisms that may involve multiple TLRs.
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Introduction
Streptococcus pneumoniae is the most frequently isolated pathogen in
community acquired pneumonia [1,2]. Several pneumococcal
proteins and enzymes have been implicated in the virulence of this
bacterium and the pathogenesis of pneumonia [3]. Pneumolysin
(PLN) is a protein expressed by Streptococcus pneumoniae intracellu-
larly and/or in the cell wall, that is present in virtually all clinical
isolates [4,5,6]. PLN is considered to be an important virulence
factor of the pneumococcus. Indeed, mice infected with a PLN-
deficient strain of S. pneumoniae showed a reduced lethality and a
diminished inflammatory response when compared to animals
infected with PLN-producing S. pneumoniae [7,8]. PLN remains
within the pneumococcus during bacterial growth, but is released
when the pathogen autodestructs by expressing autolysin [9] or
after destruction by the host immune system or antibiotic
treatment [10]. In addition, a recent report raised doubt as to
whether PLN truly is an intracellular protein, showing that PLN
primarily localized to the cell wall compartment during growth of
pneumococci in the absence of detectable cell lysis [6]. At low
doses, PLN activates the classical pathway of the complement
system, induces cytokine production by macrophages and
monocytes, inhibits the migration, respiratory burst and antibac-
terial activity of neutrophils and macrophages and affects ciliary
beating of epithelial cells [11–15]. At high doses, PLN can induce
cell death; PLN interacts with cholesterol in the host-cell
membrane resulting in the formation of transmembrane pores
and death of the host (immune) cell [16]. Our laboratory recently
demonstrated that purified PLN induces neutrophil influx and the
production of cytokines and chemokines in the lungs of mice [17].
In addition, PLN dose dependently induced vascular permeability
and pulmonary edema in mice [18,19]. Together these data
suggest that PLN has a strong impact on the host response to
invasion of the lower respiratory tract by S. pneumoniae.
Toll-like receptors (TLRs) are pattern recognition receptors that
sense the presence of microorganisms by virtue of their capacity to
recognize pathogen associated molecular patterns [20]. Recent studies
have shown that PLN is recognized by TLR4 in vitro [21–25].
Knowledge on the role of TLRs in PLN-induced inflammation in the
lung in vivo is limited: one investigation reported that the induction of
plasminogen activator inhibitor ty p e( P A I - 1 )Ig e n ee x p r e s s i o nb yP L N
in the lungs of mice at least in part depends on TLR4 [26]. The
primary objective of this study was to determine the roles of TLR2 and
TLR4 in the pulmonary effects of purified PLN in mice in vivo.
Methods
Cell Cultures
Human embryonic kidney (HEK)-293 cells [27] transfected
with CD14 and TLR2 or TLR4 (kindly provided by Douglas
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University of Massachusetts Medical School, Worcester, MA) were
grown in DMEM (1 mM pyruvate, 2 mM L-glutamine, penicillin,
streptomycin and 10% fetal bovine serum). The murine alveolar
macrophage cell line MH-S (American Type Culture Collection,
Rockville, MD) was grown in RPMI 1640 (1 mM pyruvate, 2 mM
L-glutamine, penicillin, streptomycin and 10% fetal bovine
serum). In vitro stimulation was conducted in 96-well plates
(Greiner, Alphen aan de Rijn, the Netherlands) at a density of
1610
5 cells/ml. All cell lines were allowed to adhere overnight at
37uC in a humidified atmosphere containing 5% CO2 and
stimulated the next day for 6 hours. For all stimulations, HEK
cells were co incubated with supernatant from MD-2-excreting
HEK cells [27–29] together with either highly purified PLN
(purified from Escherichia coli strain JM109 expressing a functional
pln gene as previously described [30]), lipopolysaccharide (LPS
from Escherichia coli O111:B4, Sigma Aldrich, St. Louis, MO) or
lipoteichoic acid (LTA from Staphylococcus aureus) [31]. Contami-
nation of LPS in our PLN preparation was 4.6 ng/mg PLN as
determined with the chromogenic Limulus Amoebocyte Lysate
assay (LAL assay) [32]. In some experiments polymyxin B (Sigma
Aldrich) was used at 10 mg/ml.
MTT Assay
Supernatant of stimulated cells was removed and cells were
incubated for 1–2 hours at 37uC with 100 ml 10% MTT (3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma
Aldrich) solution (5 mg/ml) in medium. Thereafter MTT solution
was replaced and cells were incubated with acetic isopropanol and
firmly resuspended to dissolve violet crystals and incubated for
10 minutes. OD of 560 nm was used to measure metabolic activity
and corrected for cell debris by OD 655 nm [33].
Animals
Specific pathogen free 8–10 weeks old C57BL/6 wild-type
(WT) mice were purchased from Charles River (Maastricht, The
Netherlands). TLR2 knockout (KO) mice and TLR4 KO mice
(kindly provided by Shizuo Akira, Exploratory Research for
Advanced Technology, Japan Science and Technology Agency,
Suita, Osaka, Japan) were generated as described previously
[34,35] and backcrossed six times to a C57BL/6 background.
All mice were bred in the animal facility of the Academic
Medical Center in Amsterdam. Age and sex matched mice were
used in all experiments. All experiments were approved by
the Animal Care and Use Committee of the University of
Amsterdam.
In Vivo Stimulation
Intranasal inoculation of PLN was performed as described
earlier [17]. Briefly, mice were lightly anesthetized by inhalation
of isoflurane (Upjohn, Ede, the Netherlands) after which 50 ml
of sterile phosphate-buffered saline (PBS) or PLN dissolved in
PBS was administered intranasally. After 6 hours, mice were
sacrificed and bronchoalveolar lavage (BAL) was performed. For
this the trachea was exposed through a midline incision and
cannulated with a 22-gauge Abbocath-T catheter (Abbott, Sligo,
Ireland). The lavage was performed by instilling two 0.5-ml
aliquots of PBS. Lavage fluid was retrieved thereafter and
counted using Z2 Coulter particle count and size analyzer
(Beckman-Coulter Inc., Miami, FL.). Differential cell counts
were determined in BAL fluid (BALF) using cytospin prepara-
tions stained with modified Giemsa stain (Diff-Quick; Baxter,
McGraw Park, Ill).
Assays
Mouse tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6,
cytokine-induced neutrophil chemoattractant (KC) and macro-
phages inflammatory protein (MIP)-2 and human IL-8 were
measured by species specific ELISA’s (R&D Systems, Minneapolis,
MN). Total protein level was measured by BCA protein assay
(Pierce, Rockford, IL).
Statistical Analysis
Data are expressed as means6SEM or median+interquartile
range. Differences were analyzed by Student T-test (in vitro cell
stimulation) or Mann Whitney U test (in vivo stimulation). A
value of P,0.05 was considered statistically significant.
Results
PLN Is Recognized by TLR4 In Vitro
Earlier studies have shown that PLN is recognized by TLR4
[21–25]. To confirm that our PLN preparation is recognized by
TLR4, we incubated HEK cells transfected with either TLR2 or
TLR4, with PLN. As positive controls for TLR4 and TLR2
signaling we also incubated HEK cells with LPS or LTA
respectively (Figure 1). HEK cells not transfected with TLR2 or
TLR4 did not respond to PLN, LPS or LTA. As expected, LTA
and LPS – induced IL-8 production was dependent on the
presence of TLR2 and TLR4 respectively (both P,0.001 versus
medium control). PLN elicited IL-8 release by HEK-TLR4
(P,0.05 versus medium control) but not by HEK-TLR2 cells.
Polymyxin B significantly inhibited LPS-TLR4 signaling but did
not influence the effect of PLN on HEK-TLR4 cells, indicating
that contaminating LPS can not explain the capacity of PLN to
stimulate TLR4. Of note, HEK-TLR4 cells spontaneously
produced more IL-8 compared to the other two HEK cell lines.
Over expression of TLR4 in HEK cells has been shown to
constitutively activate NF-kB resulting in a spontaneous activated
condition [36] which could explain the elevated spontaneous
release of IL-8. Overall, these data confirm earlier studies [21–25],
showing that PLN is recognized by TLR4.
Dose-Dependent Inflammatory and Lytic Properties of
PLN In Vitro
Alveolar macrophages in lungs can interact with PLN after
intranasal inoculation. To investigate PLN-induced cytokine
production and lysis of cells, we incubated mouse alveolar
Figure 1. PLN activates HEK cells via TLR4. IL-8 production in HEK-
293 cells transfected with CD14 and either TLR2 or TLR4 were incubated
with medium (control), LPS (100 ng/ml), LTA (5 mg/ml) or PLN (1 mg/ml)
for 6 hours. In some experiments polymyxin B (P) was used at 10 mg/ml.
Data are mean6SEM (N=4 per group). * P,0.01 versus control,
{ P,0.001 versus control, {P,0.001 versus LPS.
doi:10.1371/journal.pone.0007993.g001
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(corresponding with the observation period used in our in vivo
experiments – see further). TNF-a and MIP-2 production from
MH-S cells (Figure 2) increased dose dependently after incubation
with PLN. PLN-induced TNF-a and MIP-2 production was not
affected by the LPS inhibitor polymyxin B. PLN is known to
induce lysis of cells when incubated at high doses by inducing
pores into the cell membrane [16]. To further investigate the lytic
properties of PLN we determined cell metabolic activities by MTT
assay; a tool to measure the induction of cell death [33]. Overall
cell metabolic activity was reduced in MH-S cells incubated with
the highest PLN dose (10 mg/ml), indicative of enhanced cell
death (Figure 2; P=0.06 compared to medium control). These
data suggest that PLN activates alveolar macrophages to produce
cytokines and/or chemokines at low doses, whereas higher doses
cause cell death.
Role of TLR2 and 4 in PLN-Induced Lung Inflammation
and Injury In Vivo
Previous studies have documented the capacity of PLN to
induce lung inflammation and injury in rodents in vivo [17,18,37].
In preliminary experiments we first confirmed that PLN causes
dose-dependent effects in the lungs of WT mice upon intranasal
administration with respect to recruitment of neutrophils and
release of cytokines and chemokines into the bronchoalveolar
space, and with regard to pulmonary vascular leakage as
determined by total protein levels in BALF (see below and data
not shown). To exclude biased effects due to contaminating LPS in
our PLN preparation, we performed two control experiments.
First, we inoculated WT mice with the amount of LPS present in
our highest dose (500 ng PLN/mouse; see further) which,
according to the LAL assay, was 2 pg LPS/mouse. In addition,
we inoculated WT mice with 500 ng/mouse heat inactivated PLN
(80uC, 60 minutes), considering that LPS is heat stable. After
6 hours mice were sacrificed and differential cell counts were
determined in BALF. Mice treated with either 2 pg LPS or 500 ng
heat inactivated PLN showed a similar cellular composition of
BALF when compared with PBS treated mice, which was in
contrast to the neutrophil influx induced by PLN (Figure 3). These
data indicate that the effects produced by PLN can not be
explained by contaminating LPS. Thereafter we investigated the
roles of TLR2 and TLR4 in the effects of two PLN doses: one dose
that caused modest lung inflammation and vascular leakage
(25 ng/mouse, Figure 4) and one that caused profound lung
inflammation and injury (500 ng/mouse, Figure 5). Intranasal
administration of PLN at a dose of 25 ng induced a modest influx
of leukocytes into BALF, which was caused by an increase in the
number of alveolar macrophages and neutrophils (P,0.05 versus
PBS controls). In addition, PLN induced increases in the BALF
levels of TNF-a, MIP-2 and KC (all P,0.05 versus PBS controls),
whereas IL-6 and IL-1b concentrations remained low and similar
to PBS control mice (data not shown). Moreover, PLN 25 ng
elicited a modest rise in BALF total protein concentrations
(P,0.05 versus PBS controls). These pulmonary responses to low
dose PLN were unaltered in TLR2 and TLR4 KO mice with the
exception of KC levels in BALF of TLR4 KO mice, which were
reduced (P,0.05 compared to WT mice).
Having established that the contribution of TLR2 and TLR4 to
the lung inflammatory response to low dose PLN was negligible, we
next inoculated mice with a higher dose of PLN (500 ng/mouse). At
this dose PLN elicited macrophage and neutrophil influx, release of
IL-6, IL-1b,T N F - a and KC and a rise in total protein level in BALF
of WT mice (all P,0.05 versus PBS control). MIP-2 levels remained
low and similar to PBS control mice (data not shown). Six hours after
intranasal administration of 500 ng PLN, TLR4 KO mice displayed
reduced neutrophil influx, diminished IL-6, IL-1b and KC release
and lower total protein levels in BALF when compared with WT
Figure 2. Inflammatory and cytolytic effects of PLN on mouse alveolar macrophage MH-S cells. MH-S cells were incubated with
increasing doses of PLN for 6 hours with/without polymyxin B (10 mg/ml ) and TNF-a, MIP-2 and cell death were determined thereafter. Cell death
was measured using MTT assay as described in Methods section. Data are mean6SEM (N=5 per group). * P,0.05, { P,0.01 versus control.
doi:10.1371/journal.pone.0007993.g002
Figure 3. Cell composition in BALF of PBS-, LPS-, PLN- and heat
inactivated PLN-treated mice. Macrophage and neutrophil counts
in BALF from WT mice, 6 hours after inoculation of PBS, LPS (2 pg/
mouse), heat inactivated PLN (HIPLN 500 ng/mouse) or PLN (500 ng/
mouse). Data are plotted in Box&Whiskers graph (median+interquartile
range N=5 per group). * P,0.05 versus PBS.
doi:10.1371/journal.pone.0007993.g003
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7993Figure 4. Roles of TLR2, and TLR4 in lung inflammatory response to low dose PLN in vivo. Macrophage and neutrophil counts, total protein
and TNF-a, MIP-2 and KC concentrations in BALF from WT, TLR2 KO and TLR4 KO mice, 6 hours after inoculation of 25 ng/mouse Data are plotted in
Box&Whiskers graph (median+interquartile range N=8 per group) * P,0.05 versus WT mice. Dotted line indicates mean value of PBS-treated mice.
doi:10.1371/journal.pone.0007993.g004
Figure 5. Roles of TLR2 and TLR4 in lung inflammatory response to high dose PLN in vivo. Macrophage and neutrophil counts, total
protein, IL-6, IL-1b, TNF-a and KC concentrations in BALF from WT, TLR2 KO and TLR4 KO mice, 6 hours after inoculation of 500 ng/mouse. Data are
plotted in Box&Whiskers graph (median+interquartile range N=8 per group). * P,0.05, { P,0.01, { P,0.001 versus WT mice. Dotted line indicates
mean value of PBS-treated mice.
doi:10.1371/journal.pone.0007993.g005
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demonstrated significantly reduced BALF levels ofIL-6, KCand total
protein compared to WT mice (P,0.05). These observations were
confirmed in a second independent experiment (data not shown).
BALF TNF-a levels were similar in WT, TLR2 KO and TLR4 KO
mice. Twenty-four hours after inoculation of PLN at 500 ng/mouse,
the BALF cell composition was similar in WT, TLR2 KO and TLR4
KO mice and cytokine and chemokine levels were undetectable in all
three mouse strains (data not shown). These data suggested that the
induction of lung inflammation and injury by high dose PLN was
dependent on the presence of TLR2 and TLR4.
Discussion
The pneumococcal cell wall consists of several proteins and
enzymes that contribute to the virulence of the pathogen and the
pathogenesis of pneumonia [3]. PLN is a toxin of S. pneumonia,
expressed intracellularly and/or in the cell wall compartment, that
is present in all clinical isolates [4,5,6]. Several studies have
demonstrated that PLN is recognized by the immune system
through a specific interaction with TLR4 [21–25]. The primary
objective of the present investigation was to determine the
contribution of TLR2 and TLR4 in lung inflammation and injury
induced by PLN in vivo. First we confirmed that our PLN
preparation activated HEK cells via TLR4. We then revealed that
intrapulmonary delivery of PLN induces an inflammatory
response in the mouse lung that is dependent in part not only
on TLR4, but also on TLR2. Our data expand a recent
investigation showing that the induction of PAI-1 mRNA in the
lungs of mice at least in part depends on TLR4 [26].
Several in vitro studies have shown that low doses of PLN induce
proinflammatory reactions in immune cells like neutrophils,
macrophages, monocytes, dendritic cells and epithelial cells (10,
13, 22, 24, 37, 38). Alveolar macrophages interact with respiratory
pathogens upon invasion of the lower airways. Alveolar macro-
phages responded to PLN by production of cytokines and/or
chemokines in a dose dependent manner, whereas high PLN doses
caused cell death. Our current findings of PLN-induced lung
inflammation in WT mice confirm and extend previous studies.
Several investigations reported lung injury and leakage of the
alveolar-endothelial barrier resulting in pulmonary edema after
pulmonary instillation and aerosol delivery of PLN [19,38]. In
addition, installation of PLN resulted in depletion of the alveolar
macrophage pool and influx of neutrophils and monocytes; PLN-
induced lung injury was associated with only a small increase in
TNF-a and MIP-2 levels inBALF [38]. In a study performed earlier
in our laboratory, intranasal installation of PLN dose dependently
induced neutrophil influx and IL-6, KC and MIP-2 production in
the bronchoalveolar compartment [17]. Here we utilized this model
of PLN-induced lung inflammationto determine the contribution of
TLR2 and TLR4 to PLN effects in vivo. In line with previous in vitro
studies [21–25], PLN responses in the lungs were (in part) TLR4
dependent: in particular KC release relied on the presence of
TLR4, whereas other responses (neutrophil influx, protein leakage,
cytokine release) were significantly reduced in TLR4 KO mice only
after administration of high dose PLN. These latter findings are in
accordance with a recent study that reported attenuated induction
of PAI-1 mRNA in lungs of TLR4 KO mice upon intrapulmonary
delivery of high dose PLN [26]. Remarkably, in the current
investigation also TLR2 KO mice displayed a reduced responsive-
ness to PLN and this attenuated phenotype was not much different
from that of TLR4 KO mice. A possible explanation could be that
PLN induces endogenous ligands which may signal through TLR2
(and/or TLR4) [39,40]. One of these danger associated ligands is
hyaluronan [40]. However, BALF hyaluronan levels were even
lowerinTLR2 KOandTLR4 KOmicethan inWT mice(data not
shown), suggesting that hyaluronan concentrations in BALF may at
least in part reflect pulmonary leakage. This however does not
exclude that PLN induces other endogenous ligands which could
signal through TLR2 and/or TLR4. The concept of endogenous
TLR ligands amplifying host responses to inflammatory triggers is
supported by our recent findings that highly purified LTA, which is
an established TLR2 ligand [32,41–44], induces less profound lung
inflammation not only in TLR2 KO mice, but also in TLR4 KO
mice[45] 47).Theonlyearlierstudythatexaminedthecontribution
of TLRs in PLN-induced pulmonary effects in vivo did not address
the role of TLR2 [26]. In our experiments we could not confirm a
role for endogenous TLR2 or TLR4 expressed by alveolar
macrophages in PLN-induced KC or TNF-a release, since primary
alveolar macrophages did not respond to PLN in doses up to 1 mg/
mL (data not shown). It should be noted that PLN can induce
inflammation by mechanisms that do not rely on TLRs. In
particular, PLN exerts complement-activating activity that is
mediated by a part of the toxin that is different from that mediating
cytotoxic activity, and mutant pneumococci in which either the
cytotoxic or complement-activating activity of PLN was deleted
both showed a reduced virulence in mice [46].
Surprisingly, the lower PLN dose induced higher cytokine levels
in BALF of mice than the higher PLN dose, which was especially
true for TNF-a. Although we do not have a firm explanation for
this, differences in viability of cytokine-producing cells within the
lungs and differences in the kinetics of cytokine release into the
bronchoalveolar space upon administration of increasing PLN
doses may have played a role.
The PLN used in this study was manufactured according to the
method of Mitchell et al. which results in highly purified
pneumococcal PLN [30]. Several experiments were done to
exclude that PLN-induced effects were caused by LPS contami-
nation. First, polymyxin B, an established LPS inhibitor, did not
influence PLN effects on HEK or MH-S cells. Secondly, the
highest PLN concentration used in vivo contained 2 pg LPS/mouse
which did not induce an immune response in WT mice. In
addition, heat inactivated PLN did not induce lung inflammation
in WT mice in vivo, which - considering that LPS is heat stabile -
further argues against LPS contamination. Moreover, the addition
of soluble MD2 to HEK-TLR4 cells was absolutely required for
LPS responsiveness, confirming previous reports [27–29], whereas
PLN induced similar cytokine release by these cells in the absence
or presence of soluble MD2 (data not shown). Finally, the fact that
HEK-TLR2 cells did not respond to PLN argues against
contaminating TLR2 ligands.
PLN is a major virulence factor in S. pneumoniae infections. We
here show that PLN induces inflammation in the bronchoalveolar
compartment of mice via mechanisms that rely in part on TLR2
and TLR4. Investigations seeking to unravel the complex
interactions between pneumococcal components and host immune
cells in the lung may assist in understanding pathophysiological
mechanisms at play during pneumonia caused by S. pneumoniae.
Acknowledgments
We would like to thank Joost Daalhuisen and Marieke ten Brink for
technical assistance during animal experiments.
Author Contributions
Conceived and designed the experiments: TvdP. Performed the experi-
ments: MCD AFdV. Analyzed the data: MCD. Contributed reagents/
materials/analysis tools: RAH. Wrote the paper: MCD.
Pneumolysin and TLR
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7993References
1. Campbell GD Jr (1999) Commentary on the 1993 American Thoracic Society
guidelines for the treatment of community-acquired pneumonia. Chest 115:
14S–18S.
2. Bernstein JM (1999) Treatment of community-acquired pneumonia–IDSA
guidelines. Infectious Diseases Society of America. Chest 115: 9S–13S.
3. Jedrzejas MJ (2001) Pneumococcal virulence factors: structure and function.
Microbiol Mol Biol Rev 65: 187–207, first page, table of contents.
4. Kanclerski K, Mollby R (1987) Production and purification of Streptococcus
pneumoniae hemolysin (pneumolysin). J Clin Microbiol 25: 222–225.
5. Benton KA, Paton JC, Briles DE (1997) Differences in virulence for mice among
Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not
attributable to differences in pneumolysin production. Infect Immun 65:
1237–1244.
6. Price KE, Camilli A (2009) Pneumolysin localizes to the cell wall of
Streptococcus pneumoniae. J Bacteriol 191: 2163–2168.
7. Berry AM, Yother J, Briles DE, Hansman D, Paton JC (1989) Reduced
virulence of a defined pneumolysin-negative mutant of Streptococcus pneumo-
niae. Infect Immun 57: 2037–2042.
8. Berry AM, Paton JC, Hansman D (1992) Effect of insertional inactivation of the
genes encoding pneumolysin and autolysin on the virulence of Streptococcus
pneumoniae type 3. Microb Pathog 12: 87–93.
9. Hirst RA, Kadioglu A, O’Callaghan C, Andrew PW (2004) The role of
pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol
138: 195–201.
10. Johnson MK (1977) Cellular location of pneumolysin. FEMS Microbiol Lett 2:
243–245.
11. Houldsworth S, Andrew PW, Mitchell TJ (1994) Pneumolysin stimulates
production of tumor necrosis factor alpha and interleukin-1 beta by human
mononuclear phagocytes. Infect Immun 62: 1501–1503.
12. Paton JC, Ferrante A (1983) Inhibition of human polymorphonuclear leukocyte
respiratory burst, bactericidal activity, and migration by pneumolysin. Infect
Immun 41: 1212–1216.
13. Paton JC (1996) The contribution of pneumolysin to the pathogenicity of
Streptococcus pneumoniae. Trends Microbiol 4: 103–106.
14. Cockeran R, Durandt C, Feldman C, Mitchell TJ, Anderson R (2002)
Pneumolysin activates the synthesis and release of interleukin-8 by human
neutrophils in vitro. J Infect Dis 186: 562–565.
15. Feldman C, Mitchell TJ, Andrew PW, Boulnois GJ, Read RC, et al. (1990) The
effect of Streptococcus pneumoniae pneumolysin on human respiratory
epithelium in vitro. Microb Pathog 9: 275–284.
16. Tilley SJ, Orlova EV, Gilbert RJ, Andrew PW, Saibil HR (2005) Structural basis
of pore formation by the bacterial toxin pneumolysin. Cell 121: 247–256.
17. Rijneveld AW, van den Dobbelsteen GP, Florquin S, Standiford TJ, Speelman P,
et al. (2002) Roles of interleukin-6 and macrophage inflammatory protein-2 in
pneumolysin-induced lung inflammation in mice. J Infect Dis 185: 123–126.
18. Maus UA, Srivastava M, Paton JC, Mack M, Everhart MB, et al. (2004)
Pneumolysin-induced lung injury is independent of leukocyte trafficking into the
alveolar space. J Immunol 173: 1307–1312.
19. Witzenrath M, Gutbier B, Hocke AC, Schmeck B, Hippenstiel S, et al. (2006)
Role of pneumolysin for the development of acute lung injury in pneumococcal
pneumonia. Crit Care Med 34: 1947–1954.
20. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate
immunity. Cell 124: 783–801.
21. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, et al. (2003)
Recognition of pneumolysin by Toll-like receptor 4 confers resistance to
pneumococcal infection. Proc Natl Acad Sci U S A 100: 1966–1971.
22. Srivastava A, Henneke P, Visintin A, Morse SC, Martin V, et al. (2005) The
apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects
against pneumococcal disease. Infect Immun 73: 6479–6487.
23. Bernatoniene J, Zhang Q, Dogan S, Mitchell TJ, Paton JC, et al. (2008)
Induction of CC and CXC chemokines in human antigen-presenting dendritic
cells by the pneumococcal proteins pneumolysin and CbpA, and the role played
by toll-like receptor 4, NF-kappaB, and mitogen-activated protein kinases.
J Infect Dis 198: 1823–1833.
24. Shoma S, Tsuchiya K, Kawamura I, Nomura T, Hara H, et al. (2008) Critical
involvement of pneumolysin in production of interleukin-1alpha and caspase-1-
dependent cytokines in infection with Streptococcus pneumoniae in vitro: a
novel function of pneumolysin in caspase-1 activation. Infect Immun 76:
1547–1557.
25. Ha UH, Lim JH, Kim HJ, Wu W, Jin S, et al. (2008) MKP1 regulates the
induction of MUC5AC mucin by Streptococcus pneumoniae pneumolysin by
inhibiting the PAK4-JNK signaling pathway. J Biol Chem 283: 30624–30631.
26. Lim JH, Stirling B, Derry J, Koga T, Jono H, et al. (2007) Tumor suppressor
CYLD regulates acute lung injury in lethal Streptococcus pneumoniae
infections. Immunity 27: 349–360.
27. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, et al. (2002)
Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the
toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the
initiation of signal transduction. J Biol Chem 277: 47834–47843.
28. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, et al. (2001)
Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a
point mutation in a conserved region of MD-2 abolishes endotoxin-induced
signaling. J Exp Med 194: 79–88.
29. Visintin A, Mazzoni A, Spitzer JA, Segal DM (2001) Secreted MD-2 is a large
polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-
like receptor 4. Proc Natl Acad Sci U S A 98: 12156–12161.
30. Mitchell TJ, Walker JA, Saunders FK, Andrew PW, Boulnois GJ (1989)
Expression of the pneumolysin gene in Escherichia coli: rapid purification and
biological properties. Biochim Biophys Acta 1007: 67–72.
31. Morath S, Geyer A, Hartung T (2001) Structure-function relationship of
cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med
193: 393–397.
32. Draing C, Pfitzenmaier M, Zummo S, Mancuso G, Geyer A, et al. (2006)
Comparison of lipoteichoic acid from different serotypes of Streptococcus
pneumoniae. J Biol Chem 281: 33849–33859.
33. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Methods 65:
55–63.
34. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, et al. (1999) Differential
roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive
bacterial cell wall components. Immunity 11: 443–451.
35. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, et al. (1999) Cutting
edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to
lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol
162: 3749–3752.
36. Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M (1998) Human toll-like
receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med
188: 2091–2097.
37. Feldman C, Munro NC, Jeffery PK, Mitchell TJ, Andrew PW, et al. (1991)
Pneumolysin induces the salient histologic features of pneumococcal infection in
the rat lung in vivo. Am J Respir Cell Mol Biol 5: 416–423.
38. Maus UA, Koay MA, Delbeck T, Mack M, Ermert M, et al. (2002) Role of
resident alveolar macrophages in leukocyte traffic into the alveolar air space of
intact mice. Am J Physiol Lung Cell Mol Physiol 282: L1245–1252.
39. Tsan MF, Gao B (2004) Endogenous ligands of Toll-like receptors. J Leukoc Biol
76: 514–519.
40. Jiang D, Liang J, Fan J, Yu S, Chen S, et al. (2005) Regulation of lung injury and
repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173–1179.
41. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ (1999)
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-
like receptor 2. J Biol Chem 274: 17406–17409.
42. Ellingsen E, Morath S, Flo T, Schromm A, Hartung T, et al. (2002) Induction of
cytokine production in human T cells and monocytes by highly purified
lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit
8: BR149–156.
43. Han SH, Kim JH, Martin M, Michalek SM, Nahm MH (2003) Pneumococcal
lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating
Toll-like receptor 2. Infect Immun 71: 5541–5548.
44. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, et al. (2003)
Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus
aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-
binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved.
J Biol Chem 278: 15587–15594.
45. Dessing MC, Schouten M, Draing C, Levi M, von Aulock S, et al. (2008) Role
played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung
inflammation and coagulation. J Infect Dis 197: 245–252.
46. Alexander JE, Berry AM, Paton JC, Rubins JB, Andrew PW, et al. (1998) Amino
acid changes affecting the activity of pneumolysin alter the behaviour of
pneumococci in pneumonia. Microb Pathog 24: 167–174.
Pneumolysin and TLR
PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7993